HomeNewsQuality / GMP

US FDA inspects Indoco Remedies' solid oral formulation facility in Goa

US FDA inspects Indoco Remedies' solid oral formulation facility in Goa

The United States Food and Drug Administration (US FDA) has conducted a GMP inspection of the Solid Oral Formulation Facility (Plant 1) at Goa. The inspection was conducted from January 16 to 20, 2023.

The US FDA has issued Form 483 with 9 observations, which will be addressed within a stipulated time. We believe that this will not have an impact on the supplies and the existing revenues from this facility. The Company is committed to maintaining compliance across all our facilities with cGMP quality standards at all times.

Read more on:
Indoco Remedies USFDA
More news about: quality / gmp | Published by Sudeep Soparkar | January - 24 - 2023

Last news about this category


 

 

We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.

More information: Privacy Policy

 pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology